mRNA-derived Prostate Cancer Vaccine CV9104
Semantic Scholar uses AI to extract papers important to this topic.
- Journal for immunotherapy of cancer
CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA… (More)
- Human vaccines & immunotherapeutics
Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality… (More)
A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate… (More)
Recently, the RNActive technology has been developed to generate highly active cancer vaccines. The antigen of choice is encoded… (More)